Designing custom CRISPR libraries for hypothesis-driven drug target discovery
Over the last decade Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has been developed into a potent molecular biology tool used to rapidly modify genes or their expression in a multitude of ways. In parallel, CRISPR-based screening approaches have been developed as powerful disc...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037020303627 |
id |
doaj-4522dbaaed7845b788333524d85a502d |
---|---|
record_format |
Article |
spelling |
doaj-4522dbaaed7845b788333524d85a502d2021-01-02T05:08:55ZengElsevierComputational and Structural Biotechnology Journal2001-03702020-01-011822372246Designing custom CRISPR libraries for hypothesis-driven drug target discoveryVaishnavi Srinivasan Iyer0Long Jiang1Yunbing Shen2Sanjaykumar V. Boddul3Sudeepta Kumar Panda4Zsolt Kasza5Bernhard Schmierer6Fredrik Wermeling7Center for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; School of Physical and Mathematical Sciences, Nanyang Technological University, SingaporeCenter for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenCenter for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenCenter for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenCenter for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, SwedenCenter for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenHigh Throughput Genome Engineering, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden; Science for Life Laboratory, Stockholm, SwedenCenter for Molecular Medicine, Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Corresponding author.Over the last decade Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has been developed into a potent molecular biology tool used to rapidly modify genes or their expression in a multitude of ways. In parallel, CRISPR-based screening approaches have been developed as powerful discovery platforms for dissecting the genetic basis of cellular behavior, as well as for drug target discovery. CRISPR screens can be designed in numerous ways. Here, we give a brief background to CRISPR screens and discuss the pros and cons of different design approaches, including unbiased genome-wide screens that target all known genes, as well as hypothesis-driven custom screens in which selected subsets of genes are targeted (Fig. 1). We provide several suggestions for how a custom screen can be designed, which could broadly serve as inspiration for any experiment that includes candidate gene selection. Finally, we discuss how results from CRISPR screens could be translated into drug development, as well as future trends we foresee in the rapidly evolving CRISPR screen field.http://www.sciencedirect.com/science/article/pii/S2001037020303627 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vaishnavi Srinivasan Iyer Long Jiang Yunbing Shen Sanjaykumar V. Boddul Sudeepta Kumar Panda Zsolt Kasza Bernhard Schmierer Fredrik Wermeling |
spellingShingle |
Vaishnavi Srinivasan Iyer Long Jiang Yunbing Shen Sanjaykumar V. Boddul Sudeepta Kumar Panda Zsolt Kasza Bernhard Schmierer Fredrik Wermeling Designing custom CRISPR libraries for hypothesis-driven drug target discovery Computational and Structural Biotechnology Journal |
author_facet |
Vaishnavi Srinivasan Iyer Long Jiang Yunbing Shen Sanjaykumar V. Boddul Sudeepta Kumar Panda Zsolt Kasza Bernhard Schmierer Fredrik Wermeling |
author_sort |
Vaishnavi Srinivasan Iyer |
title |
Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
title_short |
Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
title_full |
Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
title_fullStr |
Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
title_full_unstemmed |
Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
title_sort |
designing custom crispr libraries for hypothesis-driven drug target discovery |
publisher |
Elsevier |
series |
Computational and Structural Biotechnology Journal |
issn |
2001-0370 |
publishDate |
2020-01-01 |
description |
Over the last decade Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has been developed into a potent molecular biology tool used to rapidly modify genes or their expression in a multitude of ways. In parallel, CRISPR-based screening approaches have been developed as powerful discovery platforms for dissecting the genetic basis of cellular behavior, as well as for drug target discovery. CRISPR screens can be designed in numerous ways. Here, we give a brief background to CRISPR screens and discuss the pros and cons of different design approaches, including unbiased genome-wide screens that target all known genes, as well as hypothesis-driven custom screens in which selected subsets of genes are targeted (Fig. 1). We provide several suggestions for how a custom screen can be designed, which could broadly serve as inspiration for any experiment that includes candidate gene selection. Finally, we discuss how results from CRISPR screens could be translated into drug development, as well as future trends we foresee in the rapidly evolving CRISPR screen field. |
url |
http://www.sciencedirect.com/science/article/pii/S2001037020303627 |
work_keys_str_mv |
AT vaishnavisrinivasaniyer designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT longjiang designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT yunbingshen designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT sanjaykumarvboddul designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT sudeeptakumarpanda designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT zsoltkasza designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT bernhardschmierer designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery AT fredrikwermeling designingcustomcrisprlibrariesforhypothesisdrivendrugtargetdiscovery |
_version_ |
1724359632596500480 |